Company intelligence / Profile preview

Mauna Kea Technologies

Ownership: Private
Employees: ~90
Development stage: Other

Overview

Cellvizio has received multiple FDA clearances and CE marks for use in gastrointestinal, pulmonary, urological, neurosurgical, and robot-assisted surgeries. It has been used in over 100,000 patient procedures worldwide. The platform enables real-time histological assessment during interventions to improve diagnostic accuracy and guide treatment decisions. Recent launches include CellTolerance for new applications. The company continues to expand clinical utility with AI-assisted imaging capabilities and ongoing reimbursement progress in key markets.

Therapeutic areas: GastroenterologyPulmonologyOncologyNeurology
Modalities: DeviceDiagnostic Imaging Platform
Industry: Pathology

Partnerships

Johnson & JohnsonTelix PharmaceuticalsTasly Pharmaceutical

Beyond the preview

Go deeper on Mauna Kea Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mauna Kea Technologies.

Explore the full profile